BEST MS

Best EScalation Treatment in Multiple Sclerosis (MS)

Coordinatore	CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE    more  Organization address address: "Rue Viguerie, Hotel-Dieu Saint Jacques 2" city: TOULOUSE postcode: 31059 contact info Titolo: Dr. Nome: Sophie Cognome: Mourgues Email: send email Telefono: 33561778286 Fax: 33561778411
Nazionalità Coordinatore	France [FR]
Totale costo	6˙350˙760 €
EC contributo	4˙880˙575 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2012-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-11-01   -   2016-10-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE  Organization address address: "Rue Viguerie, Hotel-Dieu Saint Jacques 2" city: TOULOUSE postcode: 31059 contact info Titolo: Dr. Nome: Sophie Cognome: Mourgues Email: send email Telefono: 33561778286 Fax: 33561778411	FR (TOULOUSE)	coordinator	2˙068˙744.00
2	PROGENIKA BIOPHARMA SA  Organization address address: "Parque Tecnologico de Zamudio, Edificio 801 -A-, Planta 2" city: DERIO - VIZCAYA postcode: 48160 contact info Titolo: Mr. Nome: Gorka Cognome: Ramirez Email: send email Telefono: +34 944064525	ES (DERIO - VIZCAYA)	participant	1˙479˙512.00
3	WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER  Organization address address: SCHLOSSPLATZ 2 city: MUENSTER postcode: 48149 contact info Titolo: Mr. Nome: Ingo Cognome: Niendorf Email: send email Telefono: 492518000000 Fax: 492518000000	DE (MUENSTER)	participant	677˙136.00
4	FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIVERSITARI VALL D'HEBRON  Organization address address: Passeig Vall d'Hebron city: BARCELONA postcode: 8035 contact info Titolo: Dr. Nome: Joan Cognome: Comella Email: send email Telefono: 34934893863 Fax: 34934894102	ES (BARCELONA)	participant	424˙320.00
5	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)  Organization address address: 101 Rue de Tolbiac city: PARIS postcode: 75654 contact info Titolo: Mrs. Nome: Muriel Cognome: Bouas Email: send email Telefono: +33 5 62 74 83 60 Fax: +33 5 61 31 97 52	FR (PARIS)	participant	230˙863.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Multiple Sclerosis (MS) is a devastating disease of the central nervous system affecting 2.5 million worldwide. MS is a field of constant therapeutic innovation, a fact which brings hope to young adults since MS is one of the most frequent causes of severe handicap. A major unmet need is to rationalize treatment decisions. To date, there is no way of predicting which patients will best respond to one of the 15 drugs expected on the market by 2014 and which patients are at risk of severe adverse effects. Recent technical advances (the omics revolution) have brought the dream of personalized medicine (PM) closer to reality. Therefore the main objective of this project is to design a composite test (using genome based biomarkers associated with clinical and radiological information) in order to predict which patients are associated with the best benefit to risk ratio in MS treatment, using Natalizumab (NTZ) as the paradigm. For this purpose, we have already built up a unique cohort of 1500 Europeans MS patients with. We will address 5 secondary objectives: #1 determine a qualitative definition of response to NTZ with clinical and radiological parameters; #2 determine a quantitative biological response test based on an in vitro assay; #3 determine DNA-based biomarkers associated with NTZ response; #4 determine genetic susceptibility to progressive multifocal encephalopathy and NTZ-related severe adverse events; and #5 determine RNA-based biomarkers associated with NTZ response. When this work is completed, we will use the data generated to build our composite test with a multivariate approach. We postulate that our predictive test for choosing the best patients to treat with NTZ will be a paradigm for all MS treatment and, beyond MS, for biotherapies in general. This project should have a positive impact on patients’ quality of life and on the MS market, and will involve a network of 5 teams (4 academic and 1 SME) that will work in perfect synergy.'

Introduzione (Teaser)

Multiple sclerosis (MS), a disease of the central nervous system, affects 2.5 million people worldwide. An EU-funded project is designing a test to help physicians make informed treatment choices.